平特五不中

Call for submissions start September 25th to November 17th, 2024.

The 平特五不中 Antimicrobial Resistance (AMR) Centre is partnering with the 平特五不中 Innovation Fund (MIF) to provide an exciting new funding opportunity to support the commercialization of research. The MIF is one of the largest entrepreneurial funding programs in the University and has already supported nearly 20 teams since its inception.

The new MIF-AMR Award would offer additional funding to teams who already secured funding in the regular MIF streams: Discover ($25,000), Develop ($50,000) and Deploy ($100,000). Successful teams will be chosen for their potential to prevent, diagnose and treat life-threatening bacterial infections. The total amount of funding available for the MIF-AMR Award is $75,000, which will be distributed at the discretion of the judging panel.

To be eligible to apply to the MIF requires an approved Report of Invention, as designated by the Office of Innovation + Partnerships. Companies who have a signed license agreement with 平特五不中 are also eligible. Full details of the award and application process are available at

听

Winners of the MIF-AMR 2023-2024 Awards 听

We were excited to welcome the two MIF-AMR winning teams at the MIF鈥檚 Passing the Torch event on February 1, 2024. The team 鈥淚taconate Antibiotic鈥� led by Profs.听Karine Auclair (平特五不中) and Andr茅anne Lupien (RI MUHC) received the Discovery MIF and MIF-AMR award ($25K + $25K), and the team 鈥淧atholyzer鈥� led by Prof. Parisa Ariya (平特五不中) received the Develop MIF and MIF-AMR ($50K + $50K). We look forward to following the success of these teams through the MIF program.